Media coverage
1
Media coverage
Title WindMIL Therapeutics Announces Dosing of First Patient in Phase 2 Clinical Study of MILs™ - NSCLC in Combination with Nivolumab (Opdivo ) for the Treatment of Non-Small Cell Lung Cancer Media name/outlet Global English (Middle East and North Africa Financial Network) Country/Territory Jordan Date 05/28/20 Persons Martin Edelman